Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RFL | PRESS-RELEASE | mixed | 7/10 | Rafael Holdings announced topline Phase 3 results for Trappsol Cyclo in Niemann-Pick Disease Type C. The primary endpoin | Sep 30, 2026 |
| KLRA | PRESS-RELEASE | neutral | 4/10 | Kailera Therapeutics completed enrollment in its KaiNETIC global Phase 3 program for ribupatide injection (KAI-9531), a | Sep 30, 2026 |
| CNTB | PRESS-RELEASE | bullish | 7/10 | Connect Biopharma reported highly positive Phase 2 topline results for rademikibart in COPD acute exacerbations, showing | Sep 30, 2026 |
| MRNA | ANALYST-DOWNGRADE | bearish | 4/10 | Citigroup double-downgraded Moderna (MRNA) from Neutral to Sell on September 30, 2026, while raising its price target fr | Sep 30, 2026 |
| SGMT | PRESS-RELEASE | bearish | 6/10 | Sagimet Biosciences priced an underwritten offering of 8,750,010 shares of Series A common stock at $10.00 per share, pl | Sep 30, 2026 |
| SGMT | 8-K | bullish | 6/10 | Sagimet announced positive 52-week results from the Phase 3 open-label extension trial (ASC40-304) of denifanstat in mod | Sep 30, 2026 |
| RADX | 6-K | neutral | 2/10 | Radiopharm Theranostics filed its annual Appendix 4G and Corporate Governance Statement for the year ended 30 June 2026, | Sep 30, 2026 |
| ANL | 6-K | neutral | 2/10 | Adlai Nortye Group Ltd. filed a 6-K reporting that all resolutions presented at its September 30, 2026 Extraordinary Gen | Sep 30, 2026 |
| PYXS | PRESS-RELEASE | bearish | 7/10 | Pyxis Oncology priced a public offering of 36M shares and 49.3M common warrants at $2.90/share, raising ~$110M in gross | Sep 30, 2026 |
| BSEM | EFFECT | bearish | 7/10 | BioStem Technologies' S-1 registration (File No. 333-299025) became effective on September 29, 2026, allowing the compan | Sep 30, 2026 |
| ABEO | CLUSTER | bearish | 4/10 | Three senior insiders at Abeona Therapeutics (CFO, Chief Legal Officer, Chief Commercial Officer) sold a combined ~$107K | Sep 29, 2026 |
| BETRF | 6-K | bullish | 7/10 | BetterLife Pharma filed its Q2 FY2027 interim financials (period ended July 31, 2026) alongside a subsequent $138.7M pub | Sep 29, 2026 |
| ADRX | CLUSTER | bullish | 6/10 | Director and 10% owner George Simeon made two open-market purchases totaling ~$17.1M at $17/share, while 10% owner SR ON | Sep 29, 2026 |
| DBVT | 8-K | bullish | 7/10 | DBV Technologies submitted a Biologics License Application (BLA) to the FDA for the VIASKIN Peanut Patch in children age | Sep 29, 2026 |
| DFTX | CLUSTER | bearish | 5/10 | Two C-suite insiders at Definium Therapeutics (CFO and CLO) sold a combined $637K in open-market sales at $36.57 per sha | Sep 29, 2026 |
| TLX | 6-K | bullish | 6/10 | Telix Pharmaceuticals announced that the FDA granted Fast Track designation for its BiPASS program, which evaluates 68Ga | Sep 29, 2026 |
| RPRX | CLUSTER | bearish | 5/10 | Two Royalty Pharma executives sold a combined $5.86M in open-market sales over a one-week window. EVP & Chairman Hite Ch | Sep 29, 2026 |
| KOD | INSIDER-BUY | bullish | 5/10 | Baker Bros. Advisors LP, a director and 10% owner, purchased 15,156 shares of Kodiak Sciences at $61.21 per share for a | Sep 29, 2026 |
| ABT | COURT-RULING | neutral | 1/10 | A federal magistrate judge in the Northern District of California issued a routine discovery order in a disability discr | Sep 29, 2026 |
| JNJ | COURT-RULING | bullish | 6/10 | JNJ subsidiary Janssen Biotech won summary judgment in a decade-old qui tam False Claims Act suit alleging that free bus | Sep 29, 2026 |
| MRVI | SC 13G | neutral | 4/10 | Millennium Management LLC filed a Schedule 13G disclosing a 5.2% passive stake in Maravai LifeSciences Holdings, Inc., r | Sep 29, 2026 |
| KURA | CLUSTER | bearish | 5/10 | Four Kura Oncology insiders, including the CSO, COO, CMO, and SVP of Finance, sold a total of ~$476K in open-market shar | Sep 29, 2026 |
| RVMD | CLUSTER | neutral | 3/10 | Three Revolution Medicines insiders sold a total of ~$804K in open-market sales over a 7-day window, with the largest sa | Sep 29, 2026 |
| PRTA | INSIDER-BUY | bullish | 5/10 | 10% owner William P. Scully purchased 103,500 shares of Prothena Corp for $890K at $8.60 per share on September 28, 2026 | Sep 29, 2026 |
| CELU | 8-K | neutral | 4/10 | Celularity appointed Naveen Jain (founder/CEO of Viome Life Sciences) to its Board, effective after a Rule 14f-1 process | Sep 29, 2026 |
| LNAI | NT 10-K | bearish | 6/10 | Lunai Bioworks filed an NT 10-K, notifying the SEC that it cannot file its annual report for the fiscal year ended June | Sep 29, 2026 |
| PHAT | 8-K | neutral | 4/10 | Phathom Pharmaceuticals announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 stud | Sep 29, 2026 |
| EQ | PRESS-RELEASE | neutral | 3/10 | Equillium announced new preclinical data for its EQ504 program, a selective AhR modulator for ulcerative colitis, to be | Sep 29, 2026 |
| DYN | PRESS-RELEASE | bullish | 7/10 | Dyne Therapeutics presented additional one-year efficacy data from the Phase 1/2 ACHIEVE trial of z-basivarsen in DM1 at | Sep 29, 2026 |
| LRMR | PRESS-RELEASE | neutral | 3/10 | Larimar Therapeutics appointed John Harlow as President and COO, effective September 29, 2026, with an inducement grant | Sep 29, 2026 |